FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978643201> ?p ?o ?g. }

• W1978643201 endingPage "472" @default.
• W1978643201 startingPage "471" @default.
• W1978643201 abstract "The optimum dose of prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (SCLC) is unknown. A meta-analysis suggested that the incidence of brain metastases might be reduced with higher PCI doses. This randomised clinical trial compared the effect of standard versus higher PCI doses on the incidence of brain metastases.Between September, 1999, and December, 2005, 720 patients with limited-stage SCLC in complete remission after chemotherapy and thoracic radiotherapy from 157 centres in 22 countries were randomly assigned to a standard (n=360, 25 Gy in 10 daily fractions of 2·5 Gy) or higher PCI total dose (n=360, 36 Gy) delivered using either conventional (18 daily fractions of 2 Gy) or accelerated hyperfractionated (24 fractions in 16 days with two daily sessions of 1·5 Gy separated by a minimum interval of 6 h) radiotherapy. All of the treatment schedules excluded weekends. Randomisation was stratified according to medical centre, age (≤60 and >60 years), and interval between the start of induction treatment and the date of randomisation (≤90, 91–180, and >180 days). Eligible patients were randomised blindly by the data centre of the Institut Gustave Roussy (PCI99-01 and IFCT) using minimisation, and by the data centres of EORTC (EORTC ROG and LG) and RTOG (for CALGB, ECOG, RTOG, and SWOG), both using block stratification. The primary endpoint was the incidence of brain metastases at 2 years. Analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov number NCT00005062.Five patients in the standard-dose group and four in the higher-dose group did not receive PCI; nonetheless, all randomised patients were included in the effectiveness anlysis. After a median follow-up of 39 months (range 0–89 months), 145 patients had brain metastases; 82 in the standard-dose group and 63 in the higher-dose group. There was no significant difference in the 2-year incidence of brain metastases between the standard PCI dose group and the higher-dose group, at 29% (95% CI 24–35) and 23% (18–29), respectively (hazard ratio [HR] 0·80 [95% CI 0·57–1·11], p=0·18). 226 patients in the standard-dose group and 252 in the higher-dose group died; 2-year overall survival was 42% (95% CI 37–48) in the standard-dose group and 37% (32–42) in the higher-dose group (HR 1·20 [1·00–1·44]; p=0·05). The lower overall survival in the higher-dose group is probably due to increased cancer-related mortality: 189 patients in the standard group versus 218 in the higher-dose group died of progressive disease. Five serious adverse events occurred in the standard-dose group versus zero in the higher-dose group. The most common acute toxic events were fatigue (106 [30%] patients in the standard-dose group vs 121 [34%] in the higher-dose group), headache (85 [24%] vs 99 [28%]), and nausea or vomiting (80 [23%] vs 101 [28%]).No significant reduction in the total incidence of brain metastases was observed after higher-dose PCI, but there was a significant increase in mortality. PCI at 25 Gy should remain the standard of care in limited-stage SCLC.Institut Gustave-Roussy, Association pour la Recherche sur le Cancer (2001), Programme Hospitalier de Recherche Clinique (2007). The European Organisation for Research and Treatment of Cancer (EORTC) contribution to this trial was supported by grants 5U10 CA11488-30 through 5U10 CA011488-38 from the US National Cancer Institute." @default.
• W1978643201 created "2016-06-24" @default.
• W1978643201 creator A5022405517 @default.
• W1978643201 creator A5063356044 @default.
• W1978643201 creator A5068565714 @default.
• W1978643201 creator A5077453712 @default.
• W1978643201 creator A5083316273 @default.
• W1978643201 creator A5083811375 @default.
• W1978643201 date "2009-09-01" @default.
• W1978643201 modified "2023-09-25" @default.
• W1978643201 title "8505 RapidArc for locally advanced head and neck cancer – first clinical results" @default.
• W1978643201 doi "https://doi.org/10.1016/s1359-6349(09)71596-4" @default.
• W1978643201 hasPublicationYear "2009" @default.
• W1978643201 type Work @default.
• W1978643201 sameAs 1978643201 @default.
• W1978643201 citedByCount "0" @default.
• W1978643201 crossrefType "journal-article" @default.
• W1978643201 hasAuthorship W1978643201A5022405517 @default.
• W1978643201 hasAuthorship W1978643201A5063356044 @default.
• W1978643201 hasAuthorship W1978643201A5068565714 @default.
• W1978643201 hasAuthorship W1978643201A5077453712 @default.
• W1978643201 hasAuthorship W1978643201A5083316273 @default.
• W1978643201 hasAuthorship W1978643201A5083811375 @default.
• W1978643201 hasConcept C120665830 @default.
• W1978643201 hasConcept C121332964 @default.
• W1978643201 hasConcept C126322002 @default.
• W1978643201 hasConcept C141071460 @default.
• W1978643201 hasConcept C146357865 @default.
• W1978643201 hasConcept C151730666 @default.
• W1978643201 hasConcept C203092338 @default.
• W1978643201 hasConcept C2776530083 @default.
• W1978643201 hasConcept C2779562246 @default.
• W1978643201 hasConcept C2989005 @default.
• W1978643201 hasConcept C44249647 @default.
• W1978643201 hasConcept C45393284 @default.
• W1978643201 hasConcept C500558357 @default.
• W1978643201 hasConcept C509974204 @default.
• W1978643201 hasConcept C535046627 @default.
• W1978643201 hasConcept C61511704 @default.
• W1978643201 hasConcept C71924100 @default.
• W1978643201 hasConcept C86803240 @default.
• W1978643201 hasConceptScore W1978643201C120665830 @default.
• W1978643201 hasConceptScore W1978643201C121332964 @default.
• W1978643201 hasConceptScore W1978643201C126322002 @default.
• W1978643201 hasConceptScore W1978643201C141071460 @default.
• W1978643201 hasConceptScore W1978643201C146357865 @default.
• W1978643201 hasConceptScore W1978643201C151730666 @default.
• W1978643201 hasConceptScore W1978643201C203092338 @default.
• W1978643201 hasConceptScore W1978643201C2776530083 @default.
• W1978643201 hasConceptScore W1978643201C2779562246 @default.
• W1978643201 hasConceptScore W1978643201C2989005 @default.
• W1978643201 hasConceptScore W1978643201C44249647 @default.
• W1978643201 hasConceptScore W1978643201C45393284 @default.
• W1978643201 hasConceptScore W1978643201C500558357 @default.
• W1978643201 hasConceptScore W1978643201C509974204 @default.
• W1978643201 hasConceptScore W1978643201C535046627 @default.
• W1978643201 hasConceptScore W1978643201C61511704 @default.
• W1978643201 hasConceptScore W1978643201C71924100 @default.
• W1978643201 hasConceptScore W1978643201C86803240 @default.
• W1978643201 hasIssue "2" @default.
• W1978643201 hasLocation W19786432011 @default.
• W1978643201 hasOpenAccess W1978643201 @default.
• W1978643201 hasPrimaryLocation W19786432011 @default.
• W1978643201 hasRelatedWork W1993014983 @default.
• W1978643201 hasRelatedWork W2137040475 @default.
• W1978643201 hasRelatedWork W2266793416 @default.
• W1978643201 hasRelatedWork W2414826575 @default.
• W1978643201 hasRelatedWork W2570154129 @default.
• W1978643201 hasRelatedWork W3116809959 @default.
• W1978643201 hasRelatedWork W4225266703 @default.
• W1978643201 hasRelatedWork W4225658851 @default.
• W1978643201 hasRelatedWork W4306253774 @default.
• W1978643201 hasRelatedWork W2241279369 @default.
• W1978643201 hasVolume "7" @default.
• W1978643201 isParatext "false" @default.
• W1978643201 isRetracted "false" @default.
• W1978643201 magId "1978643201" @default.
• W1978643201 workType "article" @default.